EyeBio secures $65 million in Series A funding
Click Here to Manage Email Alerts
EyeBio has completed a round of Series A funding, totaling $65 million, according to a press release.
The company was founded in August 2021 with the goal of developing a new generation of therapies for sight-threatening eye diseases.
“Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs,” David Guyer, MD, co-founder, president and CEO of EyeBio, said in the release. “Patients and physicians deserve new and better solutions, which is why this team of serial disruptors has banded together to form EyeBio.”
The EyeBio board of directors includes Kate Bingham, Mike Ross, PhD, Srinivas Akkaraju, MD, PhD, and Andreas Wallnoefer, PhD, in addition to co-founders Anthony P. Adamis, MD, and Guyer. Jonathan Prenner, MD, serves as chief medical officer.
The funding round was led by SV Health Investors alongside Samsara BioCapital and Jeito Capital, with additional backing from MRL Ventures.
Read more about
Click Here to Manage Email Alerts